checkAd

Nicox Provides First Quarter 2021 Business Update and Financial Highlights

Nachrichtenquelle: globenewswire
19.04.2021, 07:30  |  153   |   |   

Press Release
Nicox Provides First Quarter 2021 Business Update and Financial Highlights


  • NCX 470 Phase 3 trials in glaucoma on track for top-line results in Q2 2022 (Mont Blanc) and Q4 2022 (Denali)
  • NCX 4251 Mississippi Phase 2b trial in blepharitis on track for top-line results in Q4 2021
    • U.S. prescriptions for VYZULTA in Q1 2021 increased by 10.6% over Q1 2020, and for ZERVIATE by 29.1% over Q4 2020
  • Q1 2021 net revenue of 0.6 million and cash of €42.0 million at March 31, 2021
April 19, 2021 – release at 7:30 am CET
Sophia Antipolis, France

Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today provided a business update and financial highlights for Q1 2021 for Nicox SA and its subsidiaries (the “Nicox Group”), and updated key expected value-inflection milestones.

Key Expected Milestones

  • NCX 470 Phase 3 program in glaucoma: Nicox’s lead clinical product candidate, NCX 470, is a novel nitric oxide (NO)-donating prostaglandin analog currently in two multi-regional Phase 3 trials for the evaluation of the safety and efficacy of NCX 470 ophthalmic solution, 0.1%, against latanoprost ophthalmic solution, 0.005%, for lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Top-line results are currently expected in Q2 2022 for Mont Blanc and in Q4 2022 for Denali.  
  • NCX 4251 Phase 2b trial, Mississippi in blepharitis: NCX 4251 is a novel patented ophthalmic suspension of fluticasone propionate nanocrystals. Mississippi is evaluating once-daily dosed NCX 4251 0.1% versus placebo for the treatment of acute exacerbations of blepharitis. Top-line results are currently expected in Q4 2021.
  • We expect to enter into additional agreements for ZERVIATE (cetirizine ophthalmic solution), 0.24%, further expanding the licensed territories and increasing potential future revenue.  
  • Bausch + Lomb is planning to launch VYZULTA (latanoprostene bunod ophthalmic solution), 0.024%, in Taiwan in 2021 and in South Korea in 2022.
First Quarter 2021 and Recent Operational Highlights
Seite 1 von 5


Nicox Aktie jetzt über den Testsieger (Finanztest 11/2020) handeln, ab 0 € auf Smartbroker.de

Wertpapier



0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

Nicox Provides First Quarter 2021 Business Update and Financial Highlights Press ReleaseNicox Provides First Quarter 2021 Business Update and Financial Highlights NCX 470 Phase 3 trials in glaucoma on track for top-line results in Q2 2022 (Mont Blanc) and Q4 2022 (Denali)NCX 4251 Mississippi Phase 2b trial in blepharitis …

Nachrichten des Autors

Titel
Titel
Titel
Titel